TABLE 1.
Summarizes the demographics and comorbidities of the two groups.
| Men | Women | P Value | |
|---|---|---|---|
| n = 127,711 | n = 2,530 | ||
| Age, years (mean) | 72.89 | 70.17 | <0.001 |
| Comorbidities | |||
| Smoking | 30.7% | 33.4% | 0.003 |
| Atrial fibrillation | 30.6% | 23.6% | <0.001 |
| Coronary artery disease | 88.8% | 80.6% | <0.001 |
| Congestive heart failure | 53.7% | 45.9% | <0.001 |
| Diabetes | 54.1% | 47.8% | <0.001 |
| Hypertension | 82.5% | 81.9% | 0.47 |
| Obstructive sleep apnea | 12% | 10.3% | 0.009 |
| Peripheral artery disease | 27.7% | 18.6% | <0.001 |
| Deep vein thrombosis | 6.2% | 5.9% | 0.56 |
| Pulmonary emboli | 3.4% | 3.8% | 0.22 |
| Cirrhosis | 2.6% | 1.9% | 0.03 |
| Chronic kidney disease | 39.4% | 28% | <0.001 |
| Chronic obstructive pulmonary disease | 38.1% | 32.3% | <0.001 |
| Cerebrovascular accident | 20.5% | 19.3% | 0.16 |
| Presentation | |||
| Peak troponin levels (normal < 0.05 ng/mL) | 16.00 | 10.70 | 0.03 |
| STE-MI | 24.2% | 24.3% | 0.91 |
| Medications a | |||
| Aspirin | 88.4% | 84% | <0.001 |
| Digoxin | 15.3% | 10.4% | <0.001 |
| Hydralazine | 1% | 1% | 0.85 |
| Beta blockers | 88.1% | 82.5% | <0.001 |
| P2Y 12 inhibitors | 67.2% | 59.4% | <0.001 |
| Loop diuretics | 59.3% | 54.2% | <0.001 |
| Non-dihydropyrdines Ca blockers | 18.3% | 19.8% | 0.05 |
| Dihydropyridine Ca Blockers | 38.9% | 41.4% | 0.01 |
| Statin | 91.7% | 87.3% | <0.001 |
| Nitrates | 42.6% | 36.8% | <0.001 |
| ACE inhibitor and ARB | 87.8% | 81.5% | <0.001 |
| Interventions | |||
| CABG | 4.30% | 2.1% | <0.0001 |
| PCI | 32.0% | 28.1% | <0.0001 |
a
Medications listed were prescribed on discharge.